The public MTB Portal is an open-access version of the system that provides a lightweight implementation of the analytical pipeline used in production MTB Portal projects. This public version provides a general framework to interpret the functional relevance of genomic variants and their evidence as cancer biomarkers.

The public MTB Portal is intended for research use only. It is not certified as a medical device and should not be used for clinical decision-making. Additionally, some of the resources integrated into the system may require separate licenses for any use that is not academic research.

The public MTB Portal analyzes genomic variants, including single-nucleotide variants, small insertions/deletions, copy number alterations, and gene fusions. The input consists of user-provided variant lists; no raw sequencing data (e.g., FASTQ/BAM files) are processed.

Other data types—such as mutational signatures or gene/protein expression—are not currently supported in the public MTB Portal.

The MTB Portal integrates multiple databases and bioinformatic tools to annotate genomic variants. The report provides detailed annotation of the results, including concise summaries and direct links to the original sources of evidence as appropriate.

The MTB Portal classifies variants as: (a) Putatively functionally relevant (with evidence supporting a role in tumorigenesis), (b) Putatively neutral (no evidence of oncogenic relevance), or (c) Of unknown significance (insufficient or conflicting evidence). Evidence can derive from known effects based on clinical/preclinical data, bona fide biological assumptions, or computational predictions. Detailed rationale for each classification is provided in the report.

The MTB Portal matches genomic variants to biomarkers associated with diagnosis, prognosis, and therapeutic sensitivity or resistance. Actionability is ranked according to a modified version of the ESMO ESCAT framework. The specific evidence supporting each actionability level is detailed in the report.

The public MTB Portal processes only the genomic variants and the cancer type provided by the user. It does not accept additional patient- or tumor-specific information. Therefore, evaluations that require contextual data—such as incidental germline findings or eligibility for specific clinical trials—are only performed in MTB Portal production systems.

Your email will be used solely to create a user account. This allows the system to associate your analyses and generated reports with your account, so you can access and manage them.